| scholarly article | Q13442814 |
| P50 | author | Adam Witkowski | Q56255586 |
| Jacek Jamiołkowski | Q63126388 | ||
| Krzysztof Kukula | Q88927075 | ||
| Mariusz Klopotowski | Q91016181 | ||
| Pawel Bekta | Q114453074 | ||
| Zbigniew Chmielak | Q55392881 | ||
| P2093 | author name string | Artur Debski | |
| Aleksandra Wrobel | |||
| Joanna Was | |||
| P2860 | cites work | Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls | Q26775125 |
| Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding | Q26829251 | ||
| Platelet-reactivity tests identify patients at risk of secondary cardiovascular events: a systematic review and meta-analysis | Q27010236 | ||
| Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity | Q28196405 | ||
| High platelet reactivity on clopidogrel therapy correlates with increased coronary atherosclerosis and calcification: a volumetric intravascular ultrasound study | Q30450312 | ||
| Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of MACE in patients on clopidogrel. Systematic review and meta-analysis of individual patient data | Q31028203 | ||
| The impact of smoking on post-clopidogrel platelet reactivity in patients with acute myocardial infarction. | Q33751281 | ||
| 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventi | Q34231154 | ||
| Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis | Q34306772 | ||
| Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients with stable coronary artery disease undergoing drug-eluting stent placement | Q57243320 | ||
| 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines: An Update o | Q61667332 | ||
| Hyperreactive platelets and complications of coronary artery disease | Q69033424 | ||
| Description of response to aspirin and clopidogrel in outpatients with coronary artery disease using multiple electrode impedance aggregometry | Q83397102 | ||
| An initial experiment with personalized antiplatelet therapy: the GRAVITAS trial | Q83620035 | ||
| Do platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents?: platelet function testing and genotyping improve outcome in patients treated with antithrombotic agents | Q83630796 | ||
| Impact of smoking on antiplatelet effect of clopidogrel and prasugrel after loading dose and on maintenance therapy | Q84872696 | ||
| Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment | Q85025557 | ||
| Impaired responsiveness to the platelet P2Y12 receptor antagonist clopidogrel in patients with type 2 diabetes and coronary artery disease | Q85253139 | ||
| Advanced age and high-residual platelet reactivity in patients receiving dual antiplatelet therapy with clopidogrel or ticagrelor | Q86578829 | ||
| Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial | Q89052433 | ||
| 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevati | Q34491521 | ||
| Evaluation of clinical risk factors to predict high on-treatment platelet reactivity and outcome in patients with stable coronary artery disease (PREDICT-STABLE). | Q35208684 | ||
| Platelet aggregation and risk of stent thrombosis or bleeding in interventionally treated diabetic patients with acute coronary syndrome. | Q36216424 | ||
| Percutaneous interventions in cardiology in Poland in the year 2014. Summary report of the Association of Cardiovascular Interventions of the Polish Cardiac Society AISN PTK. | Q36245028 | ||
| The role of aspirin in cardiovascular prevention: implications of aspirin resistance | Q37158019 | ||
| The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions | Q37664571 | ||
| Cigarette smoking and clopidogrel interaction | Q38099541 | ||
| Effects of cigarette smoking on platelet reactivity during P2Y12 inhibition in patients with myocardial infarction undergoing drug-eluting stent implantation: results from the prospective cigarette smoking on platelet reactivity (COPTER) study | Q38396250 | ||
| Clinical significance of residual platelet reactivity in patients treated with platelet P2Y12 inhibitors | Q38858847 | ||
| Enhanced clopidogrel response in smokers is reversed after discontinuation as assessed by VerifyNow assay: additional evidence for the concept of 'smokers' paradox'. | Q39619414 | ||
| The Antiplatelet Effect of Clopidogrel Decreases With Patient Age. | Q40009280 | ||
| Prevalence and predictors of high-on treatment platelet reactivity with ticagrelor in ACS patients undergoing stent implantation | Q40958682 | ||
| Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease | Q41233814 | ||
| Dual low response to acetylsalicylic acid and clopidogrel is associated with myonecrosis and stent thrombosis after coronary stent implantation | Q43077318 | ||
| Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement | Q43234546 | ||
| A comparison of clopidogrel responsiveness in patients with versus without chronic renal failure | Q43258796 | ||
| Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis | Q43416611 | ||
| Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease | Q44277034 | ||
| Smoking promotes clopidogrel-mediated platelet inhibition in patients receiving dual antiplatelet therapy. | Q45920395 | ||
| Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. | Q45947797 | ||
| Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. | Q46000153 | ||
| Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. | Q46019317 | ||
| Different prognostic significance of high on-treatment platelet reactivity as assessed by the VerifyNow P2Y12 assay after coronary stenting in patients with and without acute myocardial infarction | Q46055685 | ||
| Tailored clopidogrel loading dose according to platelet reactivity monitoring to prevent acute and subacute stent thrombosis | Q46187200 | ||
| Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study. | Q46678626 | ||
| Gender Differences in Platelet Reactivity in Patients Receiving Dual Antiplatelet Therapy | Q48689443 | ||
| Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor | Q48721104 | ||
| Tailoring clopidogrel dose according to multiple electrode aggregometry decreases the rate of ischemic complications after percutaneous coronary intervention. | Q50791517 | ||
| Factors that contribute to clopidogrel resistance in cardiovascular disease patients: environmental and genetic approach. | Q51277474 | ||
| Influence of smoking on the antiplatelet effect of clopidogrel differs according to clopidogrel dose: Insights from the GRAVITAS trial. | Q51498312 | ||
| Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans. | Q51530037 | ||
| Platelet function testing in acute cardiac care - is there a role for prediction or prevention of stent thrombosis and bleeding? | Q53388110 | ||
| Predictors of high on-clopidogrel platelet reactivity in patients with acute coronary syndrome. | Q53393756 | ||
| 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribu | Q53460540 | ||
| Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. | Q53461967 | ||
| Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients. | Q54306249 | ||
| 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiol | Q55056448 | ||
| P433 | issue | 3 | |
| P921 | main subject | aspirin | Q18216 |
| clopidogrel | Q410237 | ||
| platelet aggregation | Q14913634 | ||
| P304 | page(s) | 210-217 | |
| P577 | publication date | 2017-09-25 | |
| P1433 | published in | Postępy w Kardiologii Interwencyjnej | Q26853806 |
| P1476 | title | Factors related to on-treatment platelet aggregation assessed by multiple electrode aggregometry in percutaneous coronary intervention patients on clopidogrel and aspirin | |
| P478 | volume | 13 |
Search more.